Gene therapy for hemophilia B with liver-specific element mediated by rep-RBE site-specific integration system

Journal of Cardiovascular Pharmacology

Volumn 65, Issue 2, 2015, Pages 153-159

  Xu, Zhengxin ^a,b   Ye, Juan ^a,b   Zhang, Amin ^a,b   Xie, Linjun ^a,b   Shen, Qi ^a   Xue, Jinglun ^a   Chen, Jinzhong ^a  

^a FUDAN UNIVERSITY   (China)

^b YANGZHOU UNIVERSITY   (China)

Author keywords

AAVS1 transgenic mice; gene therapy; hFIX; liver specific promoter; RBE

Indexed keywords

DNA HELICASE; BLOOD CLOTTING FACTOR 9; DNA BINDING PROTEIN; REP PROTEINS, ADENO-ASSOCIATED VIRUS 2; VIRUS PROTEIN;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CONTROLLED STUDY; GENE LOCUS; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HEMOPHILIA B; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TRANSGENIC MOUSE; VIRAL GENE THERAPY; VIRUS DNA CELL DNA INTERACTION; ANIMAL; CELL CULTURE; CHROMOSOME 19; DEPENDOPARVOVIRUS; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; HUMAN; LIVER; METABOLISM; PHYSIOLOGY; PROCEDURES;

ANIMALS; CELLS, CULTURED; CHROMOSOMES, HUMAN, PAIR 19; DEPENDOVIRUS; DNA-BINDING PROTEINS; FACTOR IX; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HEMOPHILIA B; HUMANS; LIVER; MICE; MICE, TRANSGENIC; PLASMIDS; PROMOTER REGIONS, GENETIC; VIRAL PROTEINS;

EID: 84922740028     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000172     Document Type: Article

References (25)

1. High KA. Gene therapy for haemophilia: a long and winding road. J Thromb Haemost. 2011;9:2-11.
2. Murphy SL, High KA. Gene therapy for haemophilia. Br J Haematol. 2008;140:479-487.
3. Kotin RM, Linden RM, Berns KI. Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J. 1992;11:5071-5078.
4. Chiorini JA, Yang L, Safer B, et al. Determination of adeno-associated virus Rep68 and Rep78 binding sites by random sequence oligonucleotide selection. J Virol. 1995;69:7334-7338.
5. Feng DM, Chen JZ, Yue YB, et al. A 16 bp Rep binding element is sufficient for mediating Rep-dependent integration into AAVS1. J Mol Biol. 2006;358:38-45.
6. Xu ZX, Chen JZ, Yue YB, et al. A 16 bp RBE element mediated Repdependent site-specific integration in AAVS1 transgenic mice for expression of hFIX. Gene Ther. 2009;16:589-595.
7. Nathwani AC, Gray JT, Ng CY, et al. Self-complementary adenoassociated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood. 2006;107:2653-2661.
8. Jacobs F, Snoeys J, Feng Y, et al. Direct comparison of hepatocytespecific expression cassettes following adenoviral and nonviral hydrodynamic gene transfer. Gene Ther. 2008;15:594-603.
9. Petrus I, Chuah M, VandenDriessche T. Gene therapy strategies for hemophilia: benefits versus risks. J Gene Med. 2010;12:797-809.
10. Miao CH, Ohashi K, Patijn GA, et al. Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro. Mol Ther. 2000;1:522-532.
11. Miao CH, Thompson AR, Loeb K, et al. Long-term and therapeutic-level hepatic gene expression of human factor IX after naked plasmid transfer in vivo. Mol Ther. 2001;3:947-957.
12. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 1999;6:1258-1266.
13. Zhang G, Budker V, Wolff JA. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther. 1999;10:1735-1737.
14. Song S, Lu Y, Choi YK, et al. DNA-dependent PK inhibits adenoassociated virus DNA integration. Proc Natl Acad Sci USA. 2004; 101:2112-2116.
15. Nakai H, Yant SR, Storm TA, et al. Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol. 2001;75:6969-6976.
16. Eggenhofer E, Doenecke A, Renner P, et al. High volume naked DNA tail-vein injection restores liver function in Fah-knock out mice. J Gastroenterol Hepatol. 2010;25:1002-1008.
17. Kim HS, Kim JC, Lee YK, et al. Hepatic control elements promote longterm expression of human coagulation factor IX gene in hydrodynamically transfected mice. J Gene Med. 2011;13:365-372.
18. Mayrhofer P, Schleef M, Jechlinger W. Use of minicircle plasmids for gene therapy. Methods Mol Biol. 2009;542:87-104.
19. Roth DA, Tawa NE, O'Brien JM, et al. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N Engl J Med. 2001;344:1735-1742.
20. Douglas KL. Toward development of artificial viruses for gene therapy: a comparative evaluation of viral and non-viral transfection. Biotechnol Prog. 2008;24:871-883.
21. Hafenrichter DG, Wu X, Rettinger SD, et al. Quantitative evaluation of liver-specific promoters from retroviral vectors after in vivo transduction of hepatocytes. Blood. 1994;84:3394-3404.
22. Chang AH, Stephan MT, Lisowski L, Sadelain M. Erythroid-specific human factor IX delivery from in vivo selected hematopoietic stem cells following nonmyeloablative conditioning in hemophilia B mice. Mol Ther. 2008;16:1745-1752.
23. Zhang G, Song YK, Liu D. Long-term expression of human alpha1-antitrypsin gene in mouse liver achieved by intravenous administration of plasmid DNA using a hydrodynamics-based procedure. Gene Ther. 2000;7:1344-1349.
24. Kay MA, Rothenberg S, Landen CN, et al. In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs. Science. 1993;262:117-119.
25. Schmidt EV, Christoph G, Zeller R, et al. The cytomegalovirus enhancer: a pan-active control element in transgenic mice. Mol Cell Biol. 1990;10: 4406-4411.